Search Results - "Han, Hyo Sook"

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review by Costa, Ricardo L. B., Han, Hyo Sook, Gradishar, William J.

“…Purpose Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. Although there have been advances in the treatment of…”
Get full text

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer by Han, Hyo Sook, Reis, Isildinha M, Zhao, Wei, Kuroi, Katsumasa, Toi, Masakazu, Suzuki, Eiji, Syme, Rachel, Chow, Louis, Yip, Adrian Y.S, Glück, Stefan

“…Abstract Background Racial disparities in breast cancer outcomes are attributed to differences in baseline tumour characteristics and biology, stage, age,…”
Get full text

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer by Ravi, Harshan, Arias-Lorza, Andres M, Costello, James R, Han, Hyo Sook, Jeong, Daniel K, Klinz, Stephan G, Sachdev, Jasgit C, Korn, Ronald L, Raghunand, Natarajan

“…Purpose To investigate ferumoxytol (FMX)-enhanced MRI as a pretreatment predictor of response to liposomal irinotecan (nal-IRI) for thoracoabdominal and brain…”
Get full text

Abstract P5-11-05: The cardo-oncology concerns of combining tamoxifen and ribociclib based on the TEEL trial by Ismail-Khan, Roohi, Soliman, Hatem, Hogue, Deanna, Han, Hyo Sook, Extermann, Martine, Fradley, Michael

“…Abstract Background: The TEEL Study was an open labeled, non-randomized; phase I dose escalation followed by a planned phase Ib dose expansion trial of…”
Get full text

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase by Sachdev, Jasgit C., Munster, Pamela, Northfelt, Donald W., Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Thiagalingam, Arunthathi, Anders, Carey

“…Purpose Metastatic breast cancer (mBC) remains incurable and is associated with low survival rates. This study assessed the efficacy and safety of liposomal…”
Get full text

A phase I study of indoximod in patients with advanced malignancies by Soliman, Hatem H, Minton, Susan E, Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A, Roberts, John D, Link, Charles, Vahanian, Nicholas N, Mautino, Mario, Streicher, Howard, Sullivan, Daniel M, Antonia, Scott J

“…Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum…”
Get full text

Molecular testing and the pathologist’s role in clinical trials of breast cancer by Han, Hyo Sook, Magliocco, Anthony M

“…Abstract Molecular characterization of breast cancer is pivotal for identifying new molecular targets and determining appropriate treatment choices. Advances…”
Get full text

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors by Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook

“…Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop…”
Get full text

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data by Armaghani, Avan J, Han, Hyo Sook

“…Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers…”
Get full text

Treatment of the Pregnant Patient with Breast Cancer by Shafique, Michael R, Lee, Marie Catherine, Han, Hyo Sook

“…ABSTRACTPregnancy-associated breast cancer is defined as invasive breast cancer diagnosed during gestation, within 1 year postpartum, or during lactation. Of…”
Get full text

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale by Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P

“…Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in…”
Get full text

Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between by Han, Hyo Sook, Vikas, Praveen, Costa, Ricardo L B, Jahan, Nusrat, Taye, Ammanuel, Stringer-Reasor, Erica M

“…Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The…”
Get more information

A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures by Jim, Heather S.L., Hoogland, Aasha I., Han, Hyo Sook, Culakova, Eva, Heckler, Charles, Janelsins, Michelle, Williams, Geoffrey C., Bower, Julienne, Cole, Stephen, Desta, Zeruesenay, Babilonia, Margarita Bobonis, Morrow, Gary, Peppone, Luke

“…Cancer-related fatigue is a significant problem and is associated with poor quality of life. Behavioral interventions include exercise and cognitive-behavioral…”
Get full text

Fertility and reproductive considerations in premenopausal patients with breast cancer by Lee, M Catherine, Gray, Jhanelle, Han, Hyo Sook, Plosker, Shayne

“…Approximately 10% of all new breast cancer diagnoses occur in young women. Although lacking medical comorbidities, these patients often have unique issues with…”
Get more information

Beta-catenin expression patterns in matched pre- and post-neoadjuvant chemotherapy-resistant breast cancer by Rosa, Marilin, Han, Hyo Sook, Ismail-Khan, Roohi, Allam-Nandyala, Pushpa, Bui, Marilyn M

“…β-catenin is a critical component of the cadherin cell-to-cell adhesion pathway and a key participant in the Wnt signaling pathway. Activation of β-catenin…”
Get more information

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM) by Anders, Carey, Munster, Pamela, Northfelt, Donald, Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Sachdev, Jasgit C

“…Abstract BACKGROUND: nal-IRI is a liposomal formulation of irinotecan (topoisomerase-1 inhibitor). Preclinical data show that nal-IRI accumulates in BMs and…”
Get full text

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in by Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P

“…Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in…”
Get full text

Regulation of mitosis and taxane response by Daxx and Rassf1 by Giovinazzi, S, Lindsay, C R, Morozov, V M, Escobar-Cabrera, E, Summers, M K, Han, H S, McIntosh, L P, Ishov, A M

“…Current theories suggest that mitotic checkpoint proteins are essential for proper cellular response to taxanes, a widely used family of chemotherapeutic…”
Get full text

White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia by Han, Hyo Sook, Rybicki, Lisa A., Thiel, Karl, Kalaycio, Matt E., Sobecks, Ronald, Advani, Anjali, Brown, Stacey, Sekeres, Mikkael A.

“…Kinetics of white blood cell (WBC) elimination following induction chemotherapy for older adults with acute myeloid leukemia (AML) may serve as a surrogate for…”
Get full text

Time to Nadir Peripheral White Blood Cell Count (WBC) and Absolute WBC Nadir Value Following Induction Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML) Predicts Survival by Han, Hyo Sook, Rybicki, Lisa, Kalaycio, Matt, Brown, Stacey, Advani, Anjali, Pohlman, Brad, Sobecks, Ronald, Sekeres, Mikkael

“…Older adults with AML have a poor prognosis as a result of clinical characteristics and disease biology, including chemotherapy resistance. When older adults…”
Get full text